Trial Profile
A randomized, parallel-group, phase 2 dose-finding study to evaluate the effects of BA058 in the treatment of postmenopausal women with osteoporosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2019
Price :
$35
*
At a glance
- Drugs Abaloparatide (Primary) ; Teriparatide
- Indications Postmenopausal osteoporosis
- Focus Biomarker; Therapeutic Use
- Sponsors Radius Health Inc.
- 08 Mar 2015 Post hoc analysis (Trabecular Bone Score) results presented at The 97th Annual Meeting of the Endocrine Society.
- 24 Nov 2014 Results published in a Radius Health media release and also published online in the Journal of Clinical Endocrinology & Metabolism.
- 26 Jun 2012 Results presented at the 94th Annual Meeting of the Endocrine Society.